ScreenerHero

ACET Adicet Bio, Inc.

NAS · US · Healthcare · Biotechnology · adicetbio.com
6.180USD-1.12%Mkt Cap: 57.85M $P/E: —

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prul…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap57.85M USD
Enterprise Value-38.06M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-116.80M USD
Revenue/Share—
Last Price6.180 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees102
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.55
PEG—
EV/EBITDA0.39
EV/Revenue—
P/S—
P/B0.56
EPS (TTM)-10.42
EPS (Forward)-4.04
52W Range
6.0101% of range17.44
52W High17.44 USD
52W Low6.010 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-73.36%
ROA-60.72%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-95.25M USD
CapEx (TTM)1.74M USD
FCF Margin—
FCF Yield-82.13%
Net Debt-105.34M USD
Net Debt/EBITDA1.07
Balance Sheet
Debt/Equity0.09
Current Ratio6.71
Quick Ratio6.59
Book Value/Sh11.16 USD
Cash/Share10.98 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 16, 2020
Splits
Last Split1:16
Split DateDec 30, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)34.83 USD
Upside (mean)+463.6%
Target Range18.00 USD – 90.00 USD
18.00+463.6% to mean90.00
# Analysts6
Ownership
Shares Out.9.36M
Float7.43M
Insiders1.08%
Institutions64.72%
Short Interest
Short Ratio2.3d
Short % Float2.92%
Short % Out.2.91%
Shares Short271.99K
Short (prev mo.)262.36K
Technical
SMA 508.642 (-28.5%)
SMA 2008.011 (-22.9%)
Beta1.63
S&P 52W Chg16.45%
Avg Vol (30d)225.86K
Avg Vol (10d)484.01K
Technical Indicators
RSI (14)33.4
MACD-0.7097
MACD Signal-0.4597
MACD Hist.-0.2500
BB Upper10.83 USD
BB Middle8.096 USD
BB Lower5.360 USD
BB Width67.58%
ATR (14)0.6238 USD
Vol Ratio (20d)0.74x